Diffinity Genomics acquired by Chiral Technologies. Read more...
Diffinity Genomics issued patent for their technology "Spatially inhomogenously functionalized porous media and method for use in selective removal of contaminants". The patent was issued June 23, 2015.
Diffinity Genomics’ products are based on a platform technology for chemically sequestering nucleic acids through selective adsorption. This differential affinity (“diffinity”) can be used in many ways, including cleaning mixtures of DNA or RNA as well as testing for the presence or absence of a specific genetic target.
Diffinity technology breaks traditional nucleic acid cleaning paradigms by directly binding impurities (such as nucleotides, primers, and primer-dimers) on our proprietary surfaces while allowing double stranded DNA targets (such as PCR amplicons) to remain in solution. This methodology allows simple, rapid, and inexpensive cleanup inside a pipette tip or column without any additional buffers or reagents. Our technology can be applied in two areas: